1. Home
  2. AIV vs LYEL Comparison

AIV vs LYEL Comparison

Compare AIV & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apartment Investment and Management Company

AIV

Apartment Investment and Management Company

N/A

Current Price

$2.42

Market Cap

374.7M

Sector

Real Estate

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$11.96

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIV
LYEL
Founded
1975
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
374.7M
320.1M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
AIV
LYEL
Price
$2.42
$11.96
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$10.00
$30.60
AVG Volume (30 Days)
969.2K
92.9K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
87.41%
N/A
EPS Growth
616.00
N/A
EPS
N/A
N/A
Revenue
$138,486,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.46
$11.47
52 Week High
$8.03
$45.00

Technical Indicators

Market Signals
Indicator
AIV
LYEL
Relative Strength Index (RSI) 26.67 35.26
Support Level N/A $11.59
Resistance Level $2.74 $14.14
Average True Range (ATR) 0.05 0.81
MACD -0.00 -0.30
Stochastic Oscillator 4.55 4.37

Price Performance

Historical Comparison
AIV
LYEL

About AIV Apartment Investment and Management Company

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: